The primary objective of this Interim Guidance is to review evidence on the safety and immunogenicity of PNEU-C-15 in the pediatric age group and to develop interim recommendations on its interchangeability with PNEU-C-13 for use in routine pediatric schedules as well as for children at high risk of IPD.

  • Recommendation
  • Americas
  • Canada
  • Newborn
  • Pneumococcal disease